Sell4

UNITED THERAPEUTICS Corp

UTHR

Total Value

$7.9M

Net $5.7M sold

Filing Date

Oct 30, 2026

9 transactions

Sales

$5.7M

9 transactions

Trade Summary

On Oct 29, 2026, ROTHBLATT MARTINE A, Insider, sold $7.9M of UNITED THERAPEUTICS Corp (UTHR) across 9 transactions. The filing covers Common Stock and reflects net selling of $5.7M. Reported prices ranged from $117.76 to $599.30. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

UTHR daily price with the insider's sale marked at $594.78.

Sold near the 6-month high · about level with today's price.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: ROTHBLATT MARTINE A
Role: Insider
Location: SILVER SPRING, MD

Filing Details

Filing Date: Oct 30, 2026
Transaction Date: Oct 29, 2026
Accession Number: 0001106578-26-000175
Form Type: 4
Net Trading Amount: -$5.7M

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Oct 29, 2026	Common Stock	9,500	$117.76	Exercise	$1.1M
Oct 29, 2026	Common Stock	53	$590.43	Sale	$31.3K
Oct 29, 2026	Common Stock	1,104	$591.90	Sale	$653.5K
Oct 29, 2026	Common Stock	1,563	$592.97	Sale	$926.8K
Oct 29, 2026	Common Stock	1,540	$593.88	Sale	$914.6K
Oct 29, 2026	Common Stock	1,248	$594.89	Sale	$742.4K
Oct 29, 2026	Common Stock	1,678	$595.88	Sale	$999.9K
Oct 29, 2026	Common Stock	1,355	$596.86	Sale	$808.7K
Oct 29, 2026	Common Stock	919	$597.66	Sale	$549.2K
Oct 29, 2026	Common Stock	40	$599.30	Sale	$24.0K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Oct 29, 2026	UTHR derivative	9,500	$117.76	Exercise	$1.1M

Want live alerts when ROTHBLATT MARTINE A trades again?

Download Insider Trades to track UTHR, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
(F10)This transaction was executed in multiple trades at prices ranging from $597.41 to $598.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(F11)Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
(F12)Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
(F13)Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
(F14)These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
(F15)Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
(F2)Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
(F3)This transaction was executed in multiple trades at prices ranging from $590.17 to $590.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(F4)This transaction was executed in multiple trades at prices ranging from $591.33 to $592.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(F5)This transaction was executed in multiple trades at prices ranging from $592.36 to $593.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(F6)This transaction was executed in multiple trades at prices ranging from $593.39 to $594.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(F7)This transaction was executed in multiple trades at prices ranging from $594.41 to $595.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(F8)This transaction was executed in multiple trades at prices ranging from $595.41 to $596.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(F9)This transaction was executed in multiple trades at prices ranging from $596.41 to $597.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTHBLATT MARTINE A

(Last)

(First)

(Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING

20910

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairperson & CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/29/2026		M⁽¹⁾		9,500	A	$117.76	333,943	I	by Trust⁽²⁾
Common Stock	10/29/2026		S⁽¹⁾		53	D	$590.4296⁽³⁾	333,890	I	by Trust⁽²⁾
Common Stock	10/29/2026		S⁽¹⁾		1,104	D	$591.902⁽⁴⁾	332,786	I	by Trust⁽²⁾
Common Stock	10/29/2026		S⁽¹⁾		1,563	D	$592.9686⁽⁵⁾	331,223	I	by Trust⁽²⁾
Common Stock	10/29/2026		S⁽¹⁾		1,540	D	$593.8794⁽⁶⁾	329,683	I	by Trust⁽²⁾
Common Stock	10/29/2026		S⁽¹⁾		1,248	D	$594.8947⁽⁷⁾	328,435	I	by Trust⁽²⁾
Common Stock	10/29/2026		S⁽¹⁾		1,678	D	$595.8794⁽⁸⁾	326,757	I	by Trust⁽²⁾
Common Stock	10/29/2026		S⁽¹⁾		1,355	D	$596.8608⁽⁹⁾	325,402	I	by Trust⁽²⁾
Common Stock	10/29/2026		S⁽¹⁾		919	D	$597.6552⁽¹⁰⁾	324,483	I	by Trust⁽²⁾
Common Stock	10/29/2026		S⁽¹⁾		40	D	$599.3	324,443	I	by Trust⁽²⁾
Common Stock								40,513	D
Common Stock								166	I	by Spouse
Common Stock								249,108	I	by Trust⁽¹¹⁾
Common Stock								45,596	I	by Trust⁽¹²⁾
Common Stock								8,902	I	by Trust⁽¹³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$117.76	10/29/2026		M⁽¹⁾			9,500	⁽¹⁴⁾	03/15/2027	Common Stock	9,500	$0.00	128,910	I	by Trust⁽¹⁵⁾

Explanation of Responses:

1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.

2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

3. This transaction was executed in multiple trades at prices ranging from $590.17 to $590.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $591.33 to $592.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $592.36 to $593.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $593.39 to $594.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $594.41 to $595.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $595.41 to $596.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $596.41 to $597.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $597.41 to $598.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

12. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

13. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

14. These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.

15. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001106578-26-000175.

UNITED THERAPEUTICS Corp

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when ROTHBLATT MARTINE A trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4

Price at the Time of the Trade